RT Journal
A1 Del Brutto OH
T1 ALbendazole therapy for neurocysticercosis
JF Archives of Neurology
JO Archives of Neurology
YR 1990
FD December 1
VO 47
IS 12
SP 1278
OP 1278
DO 10.1001/archneur.1990.00530120018003
UL http://dx.doi.org/10.1001/archneur.1990.00530120018003
AB To the Editor. 
    —I have read with interest the article by Alarcón et al,1 as it showed that the length of albendazole therapy for parenchymal brain cysticercosis could be considerably shortened without lessening its efficacy. The authors did not state, however, how the 3-day course of albendazole treatment was chosen. Was it chosen on an empirical basis? If so, a larger number of patients was needed to support their findings.Albendazole is an imidazole with intense antiparasitic properties that has largely replaced praziquantel as the drug of choice for parenchymal brain cysticercosis.2-4 The initial length of 30 days of albendazole therapy for neurocysticercosis5 was settled according to that previously used for the treatment of human hydatidosis.6 When treating patients with cysticercosis, however, two observations suggested that the therapeutic effect of the drug occurred far before the full course of 30 days was completed: first, most patients